Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura: A case report and concise review of the literature

Swiss Medical Weekly

Volumn 137, Issue 37-38, 2007, Pages 518-524

  Rüfer, Axel ^a   Brodmann, Doreen ^a   Gregor, Michael ^a   Hovinga, Johanna A Kremer ^b   Lämmle, Bernhard ^b   Wuillemin, Walter A ^a  

^a LUZERNER KANTONSSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Acute refractory thrombotic thrombocytopenic purpura; ADAMTS 13; Rituximab; TTP

Indexed keywords

ANTICOAGULANT AGENT; CORTICOSTEROID; GLUCOCORTICOID; PREDNISONE; RITUXIMAB; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ABSCESS DRAINAGE; ADULT; CASE REPORT; DRUG SAFETY; ENZYME DEFICIENCY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG EMBOLISM; PLASMA TRANSFUSION; PLASMAPHERESIS; PLEURA EMPYEMA; REMISSION; SHORT SURVEY; SPLENECTOMY; SUBPHRENIC ABSCESS; THORACOTOMY; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE;

EID: 35348939701     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (31)

1. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: A hitherto undescribed disease. Proc NY Pathol Soc. 1924;24:21-4.
2. George JN. Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2006;354:1927-35.
3. Lämmle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost. 2005;3:1663-75.
4. Terrell DR, Williams LA, Vesely SK, Lämmle B, Kremer Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005;3:1432-6.
5. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393-7.
6. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578-84.
7. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-94.
8. Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60-8.
9. Böhm M, Betz C, Miesbach W, Krause M. von Auer C, Geiger H, et al. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol. 2005; 129:644-52.
10. Ziman A, Mitri M, Klapper E, Pepkowitz SH, Goldfinger D. Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution's experience and review of the literature. Transfusion. 2005:45:41-9.
11. Allford SL, Hunt BJ, Rose P, Machin S. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol. 2003;120:556-73.
12. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology 2004. Washington DC: American Society of Hematology. 2004:407-23.
13. Kremer Hovinga JA, Studt JD, Demarmels Biasiutti F, Solenthaler M, Alberio L, Zwicky C, et al. Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Haematologica. 2004;89:320-4.
14. Kappers-Klunne MC, Wijermans P, Fijnheer R, Croockewit AJ, van der Holt B, de Wolf JT, et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol. 2005;130:768-76.
15. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146:25-33.
16. Studt JD, Böhm M, Budde U, Girma JP, Varadi K, Lämmle B. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost. 2003;1:1882-7.
17. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol. 2004;124:787-95.
18. Chemnitz J, Draube A, Scheid C, Schulz A, Diehl V, Sohngen D. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol. 2002;71:105-8.
19. Sallah S, Husain A, Wan JY, Nguyen NP. Rituximab in patients with refractory thrombotic thrombocytopenic purpura. J Thromb Haemost. 2004;2:834-6.
20. Koulova L, Alexandrescu D, Dutcher JP, O'Boyle KP, Eapen S, Wiernik PH. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Am J Hematol. 2005;78:49-54.
21. Millward PM, Bandarenko N, Chang PP, Stagg KF, Afenyi-Annan A, Hay SN, Brecher ME. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion. 2005;45: 1481-6.
22. Scott SM, Szczepiorkowski ZM. Rituximab for TTP. Am J Hematol. 2005;80:87-8.
23. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood. 2005; 106:1932-7.
24. Darabi K, Berg AH. Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol. 2006;125:592-97.
25. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2006;136:451-61.
26. Fontana S, Kremer Hovinga JA, Studt JD, Alberio L, Lämmle B, Mansouri Taleghani B. Plasma therapy in thrombotic thrombocytopenic purpura: Review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Semin Hematol. 2004;41:48-59.
27. Pereira A, Mazzara R, Monteagudo J, Sanz C, Puig L, Martinez A, et al. Thrombotic thrombocytopenic purpura/haemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol. 1995;70:319-23.
28. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. British Committee for Standards in Haematology, Blood Transfusion Task Force. Br J Haematol. 2004;126:11-28.
29. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103:4043-9.
30. Rizvi MA, Vesely SK, George JN, Chandler L, Duvall D, Smith JW, et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura - hemolytic-uremic syndrome. Transfusion. 2000;40:896-901.
31. George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Haemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher. 2006; 21:49-56.